The Prognostic Value of Biomarkers Identified by [18F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy
Anne-Line Mayland Madsen, Oke Gerke, Christina H. Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja · 2025
Read The Prognostic Value of Biomarkers Identified by [18F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy by Anne-Line Mayland Madsen, Oke Gerke, Christina H. Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785806.txt.
Description
Anne-Line Mayland Madsen and co-authors test whether scan-based markers predict outcomes for high-risk melanoma patients given immune therapy after surgery. The therapy improves freedom from recurrence but causes side effects in many. Scans that track sugar use in tissue might flag immune side effects and organ activity ratios tied to outlook.
In a Danish register cohort, over half the patients saw their cancer return and a quarter died during follow-up. Most showed at least one scan-detected immune side effect. Those side effects did not predict overall survival, and early ones were linked to higher recurrence risk, opposite to some prior reports. Ratios for spleen and bone marrow showed no prognostic value.
Catalog record
| CREATOR | Anne-Line Mayland Madsen, Oke Gerke, Christina H. Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |